Nanjing Medical University First Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication

Early Phase 1

Not yet recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Vonoprazan
Drug: Amoxicillin
Drug: Zuojin Wan

First Posted Date: 2025-03-28

Last Posted Date: 2025-03-28

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 136

Registration Number: NCT06901375

Locations: 🇨🇳
Nanjing First Hospitai, Nanjing, Jiangsu, China

The Impact of Ultrasound-Guided Superficial and Deep Paravertebral Nerve Blocks at the Superior Costotransverse Ligament on Hemodynamics During the Induction Phase of Thoracoscopic Lung Lobectomy: A Multicenter, Double-Blind, Randomized Controlled Trial

Not Applicable

Recruiting

Conditions: Thoracic Paravertebral Block
Anesthesia Induction
Hypotension on Induction

First Posted Date: 2025-02-24

Last Posted Date: 2025-05-25

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 168

Registration Number: NCT06841822

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China

Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes

Phase 3

Recruiting

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Outpatient newly diagnosed type 2 diabetes subjects
Drug: Inpatient newly diagnosed type 2 diabetes subjects

First Posted Date: 2025-02-13

Last Posted Date: 2025-02-13

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 1000

Registration Number: NCT06825182

Locations: 🇨🇳
Nanjing First Hostital, Nanjing, Jiangsu, China

Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial

Not yet recruiting

Conditions: Small Cell Lung Cancer Extensive Stage
ELDERLY PEOPLE

First Posted Date: 2025-02-13

Last Posted Date: 2025-02-13

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 29

Registration Number: NCT06825208

Clinical Study of Perioperative Sleep Disorders in Cardiac Surgery

Phase 4

Recruiting

Conditions: Sleep Wake Disorders
Esketamine and the Quality of Recovery
Dexmedetomidine

Interventions: Drug: Intraoperative infusion of dexmedetomidine
Drug: Intraoperative infusion of esketamine
Drug: Saline control

First Posted Date: 2025-01-16

Last Posted Date: 2025-02-07

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 180

Registration Number: NCT06778811

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
🇨🇳
Nanjing First Hospital，Nanjing Medical University, Nanjing, Jiangsu, China

The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

Early Phase 1

Not yet recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Keverprazan
Drug: Amoxicillin
Drug: Furazolidone
Drug: Colloidal Bismuth Pectin

First Posted Date: 2025-01-16

Last Posted Date: 2025-01-16

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 672

Registration Number: NCT06777732

Effect of Subanesthetic Dose of Esketamine on Sleep Quality

Not Applicable

Recruiting

Conditions: Insomnia
Breast Cancer Surgery
Esketamine

Interventions: Drug: Esketamine at low dose
Other: Normal Saline (0.9% NaCl)

First Posted Date: 2025-01-14

Last Posted Date: 2025-02-10

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 184

Registration Number: NCT06773143

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China

Effect of Percutaneous Electrical Acupoint Stimulation on the Improvement of Incidence of Adverse Respiratory Events

Not Applicable

Recruiting

Conditions: Extubation
Respiratory Depression
Acupuncture Points
Hypoxia

First Posted Date: 2025-01-14

Last Posted Date: 2025-02-10

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 236

Registration Number: NCT06772961

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China

Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis

Not Applicable

Not yet recruiting

Conditions: Rosacea
Acne
Centella
Melasma

First Posted Date: 2025-01-08

Last Posted Date: 2025-01-08

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 30

Registration Number: NCT06763367

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

Phase 2

Not yet recruiting

Conditions: Solid Tumors

Interventions: Drug: Ensartinib

First Posted Date: 2025-01-07

Last Posted Date: 2025-01-07

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 20

Registration Number: NCT06762327

AI-Powered Research

Premium Access

Nanjing Medical University First Hospital

Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication

The Impact of Ultrasound-Guided Superficial and Deep Paravertebral Nerve Blocks at the Superior Costotransverse Ligament on Hemodynamics During the Induction Phase of Thoracoscopic Lung Lobectomy: A Multicenter, Double-Blind, Randomized Controlled Trial

Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes

Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial

Clinical Study of Perioperative Sleep Disorders in Cardiac Surgery

The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

Effect of Subanesthetic Dose of Esketamine on Sleep Quality

Effect of Percutaneous Electrical Acupoint Stimulation on the Improvement of Incidence of Adverse Respiratory Events

Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer